ReviewVascular medicine (London, England)2022
Livedoid vasculopathy: A review with focus on terminology and pathogenesis.
Review in Vascular medicine (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Livedoid Vasculopathy Mimicking Rheumatoid Vasculitis in a Patient With Active Rheumatoid Arthritis.Cureus · 2026Article
- Antiphospholipid Syndrome-Associated Livedoid Vasculopathy Mimicking Recurrent Periprosthetic Joint Infection after Total Knee Arthroplasty: A Case Report.Journal of orthopaedic case reports · 2026Article
- A Double Diagnosis Behind Chronic Ulcers: Livedoid Vasculopathy With Acroangiodermatitis in an Elderly Woman.Cureus · 2026Article
- Refractory livedoid vasculopathy successfully treated with immunosuppressive therapy.JAAD case reports · 2025Article
- Successful healing of a chronic ulcer in livedoid vasculopathy using PuraPly: A case report.JAAD case reports · 2025Article
- A case report and literature review of livedoid vasculopathy in children.Frontiers in pediatrics · 2025Article
- Clinical Characteristics and Disease Course of Livedoid Vasculopathy: A 10-Year Retrospective Analysis.Clinical, cosmetic and investigational dermatology · 2025Article
- Successful Treatment of Refractory Livedoid Vasculopathy with Upadacitinib: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Prevalence of Livedoid Vasculopathy Among Patients with Connective Tissue Diseases and Its Association with Thrombophilic Factors: A Hospital-Based Retrospective Cohort (2014-2021).Clinical, cosmetic and investigational dermatology · 2025Article
- Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers.Annals of hematology · 2024Article
- Dermatologic manifestations of hematologic disorders.Annals of hematology · 2024Review
- The muscle pump activator device: From evidence to lived experiences.International wound journal · 2024Review
- The potential role of tumor necrosis factor-α in thrombosis in livedoid vasculopathy.Archives of dermatological research · 2024Article
- Healing refractory livedoid vasculopathy-related skin ulcers by ozone therapy: a case-based review.Rheumatology international · 2024Review
- Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series.Clinical, cosmetic and investigational dermatology · 2024Article
- Identification of Challenging Diagnostic Factors in Livedoid Vasculopathy: A Retrospective Study.Clinical, cosmetic and investigational dermatology · 2024Article
- Evaluating complement dysregulation in livedoid vasculopathy using a functional assay.Blood advances · 2023Article
- Vascular Disease Patient Information Page: Livedoid vasculopathy.Vascular medicine (London, England) · 2022Article
- Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.